← The patent line

Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium

Sold as XACDURO (COPACKAGED) · given by intravenous

Five to ten years until it comes off patent
9.2 yr
Until anyone may copy it
Protection runs to 2035-11-17
4
Trials running now
9 registered in total
Phase 3
Furthest stage reached
large trials measuring benefit
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Entasis Therapeutics Inc
Approval holder
the only company permitted to sell it today
2035-11
Last patent expires
latest patent filed against this product
2033-05
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Acinetobacter Baumannii-calcoaceticus Acinetobacter Baumannii-calcoaceticus Carbapenem-Resistant Acinetobacter Bau
03

Who is paying for the research

Entasis Therapeutics
Company
5
Innoviva Specialty Therapeutics
Company
2
Sichuan Provincial People's Hospit
University or hospital
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07485010Phase 22027 · 300 people · not yet recruiting
Testing a Novel Combination Treatment (Arm D

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line